|Original language||English (US)|
|Number of pages||6|
|Journal||Journal of the American Academy of Child and Adolescent Psychiatry|
|State||Published - Mar 2007|
Bibliographical noteFunding Information:
Disclosure: None of the authors have conducted industry-funded studies of clozapine. Drs. Kumra, Kranzler, and Gerbino-Rosen have conducted studies of clozapine funded by the National Institute of Mental Health, but with study drug donated by Novartis. Dr. Kratochvil was previously a speaker for Novartis and has received grant support from, is a consultant to, and/or member of the speakers' bureaus of Eli Lilly, GlaxoSmithKline, Forest, Shire, Cephalon, Novartis, McNeil, Organon, AstraZeneca, and Pfizer. Dr. Findling has been a consultant to and conducted studies for Novartis, the manufacturer of Clozaril, and receives or has received research support from, acted as a consultant to, and/or served on the speakers' bureaus of Abbott, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Forest, GlaxoSmithKline, Johnson & Johnson, Lilly, New River, Novartis, Otsuka, Pfizer, Sanofi-Aventis, Shire, Solvay, and Wyeth. Dr. Frazier has received research support from, acted as a consultant to, and/or served on the speakers' bureaus of AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Research Institute, Johnson & Johnson Pharmaceutical Research and Development, Otsuka Pharmaceutical Inc., and Pfizer. The other authors have no financial relationships to disclose.
Copyright 2018 Elsevier B.V., All rights reserved.